Sanofi-aventis, GPSA Sign License Agreement
According to Sanofi-aventis, those agents are vanilloid receptor (TRPV3) antagonist molecules, including a first-in-class clinical compound, GRC 15300, which is currently in Phase I clinical development as a potential next-generation treatment for various pain conditions, including diabetic neuropathic pain and osteoarthritic pain.
Under the terms of the agreement, Glenmark will receive an upfront payment as well as development, regulatory and commercial payments. All such payments could reach a total of $32.5m.
In addition, Glenmark is eligible to receive tiered royalties on sales of products commercialized under the license. Sanofi-aventis will have marketing rights in North America, European Union and Japan, subject to Glenmark's right to co-promote the products in the US and five Eastern European countries.
Sanofi-aventis will also have co-marketing rights in 10 other countries including Brazil, Russia and China whereas Glenmark will retain exclusive rights in India and other countries of the rest of the world.
The TRPV3 receptor is an ion channel protein that mediates and influences cell signaling, including the nerve cell signaling that generates some types of pain.
Marc Cluzel, executive vice president of research and development at sanofi-aventis, said: “There continues to be a medical need for safer and more efficacious products for the treatment of painful diabetic neurophathy and osteoarthritis pain. GRC 15300 brings an innovative approach to sanofi-aventis’ pain portfolio, which we believe may have promise to address a significant gap in treating chronic pain.”
Glenn Saldanha, CEO of GPL, said: “This agreement continues to demonstrate Glenmark’s R&D and validates Glenmark’s leadership in the Indian drug discovery arena. We have made progress with our TRPV3 program at Glenmark and are very excited to be joining our efforts with those of sanofi aventis, a research-driven pharmaceutical company.”
Will this agreement help the firms to progress in TRPV3 program?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.